Our objective
To bring to market the first drug that sensitises cancer cells to cancer therapies, to improve the survival outcomes of standard chemotherapy and radiotherapy, and allow effective dosages of standard chemotherapy and radiotherapy to be lowered to non-toxic levels, and thereby provide treatment options for the elderly and frail and the significant population of patients who elect not to undergo toxic therapies.
To view Presentation please download PDF attached:
Download this document
